Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice
Related Experiment Video
Updated: Aug 6, 2026
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
1Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. chung2@jhmi.edu
Abstract:
Vaccinia virus has been shown to efficiently infect tumor cells. Therefore, vaccinia virus represents a potentially safe and effective antitumor agent against ovarian cancer. Here, we assessed the ability of vaccinia virus to preferentially infect and control both human and murine ovarian tumors in vivo. We used the non-invasive luminescence imaging system to monitor the infection and suppression of ovarian tumors by vaccinia in live mice. Our data indicated that vaccinia was able to effectively infect and kill both human and murine ovarian tumors. Vaccinia virus administered to mice intraperitoneally was specifically targeted to the murine or human ovarian tumors and led to antitumor responses. These findings suggest that vaccinia virus is capable of selectively targeting and controlling ovarian tumors. Thus, intraperitoneal injection with vaccinia virus may provide a potentially effective strategy for treating advanced-stage ovarian cancers.
Insights
Vaccinia virus effectively infects and controls ovarian tumors in mice. Intraperitoneal vaccinia virus injection shows promise as a novel antitumor strategy for ovarian cancer.
Area of Science:
- Oncolytic virology
- Cancer immunotherapy
- Ovarian cancer research
Background:
- Vaccinia virus demonstrates efficient tumor cell infection.
- Ovarian cancer remains a significant health challenge requiring novel therapeutic approaches.
Purpose of the Study:
- To evaluate vaccinia virus's efficacy in targeting and controlling both human and murine ovarian tumors in vivo.
- To assess the potential of vaccinia virus as an antitumor agent for ovarian cancer.
Main Methods:
- Utilized non-invasive luminescence imaging to monitor tumor infection and suppression in live mice.
- Administered vaccinia virus intraperitoneally to mice bearing human or murine ovarian tumors.
Main Results:
- Vaccinia virus effectively infected and reduced ovarian tumors in both human and murine models.
- Intraperitoneal administration led to specific targeting of ovarian tumors and induced antitumor responses.
- Demonstrated selective infection and control of ovarian tumors by vaccinia virus.
Conclusions:
- Vaccinia virus exhibits selective targeting and control capabilities against ovarian tumors.
- Intraperitoneal vaccinia virus injection presents a potential therapeutic strategy for advanced-stage ovarian cancers.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...